



CODEN [USA]: IAJPBB

ISSN: 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES<http://doi.org/10.5281/zenodo.4452684>Available online at: <http://www.iajps.com>

Research Article

**ASSESSMENT OF ROLE OF GHRELIN AMONG YOUNG
HYPERTENSIVE AND OBESE PATIENTS**Dr Muhammad Bilal Iftikhar¹, Dr Ijaz Ahmed², Dr Sarmad Elahi¹¹Islamic International Medical College Rawalpindi (RIU),²Bahawal Victoria Hospital, Bahawalpur.

Article Received: April 2019

Accepted: May 2019

Published: June 2019

Abstract

Introduction: Overweight is a body mass index between 25.0 to 29.9 kg/m². Obesity is a body mass index of 30 kg/m² or higher.

Objectives of the study: The main objective of the study is to analyse the role of Ghrelin among young hypertensive and obese patients.

Methodology of the study: This cross-sectional study was conducted in Islamic International Medical College Rawalpindi (RIU) during August 2018 to March 2019. The data was collected from 100 patients. A fasting venous blood sample with a total volume of 4 ml will be collected from each study participant. One ml of this will be used in for routine testing FBS and 1 ml for fasting lipid profile.

Results: The data was collected from 100 patients, 50 were obese and 50 were normotensive patients. Minimum age was age was 10 years and maximum age was 25 years with mean age 39.35 ± 10.086 years. Mean age of hypertensive obese was 43.42 ± 10.466 years and mean age of normotensive was 35.28 ± 7.876 years. **Conclusion:** It is concluded that Ghrelin was positively associated with hypertension in obese patients and this association was inversely influenced by the increase of BMI.

Corresponding author:

Dr Muhammad Bilal Iftikhar,

Islamic International Medical College Rawalpindi (RIU).

QR code



Please cite this article in press Muhammad Bilal Iftikhar et al., *Assessment Of Role Of Ghrelin Among Young Hypertensive And Obese Patients.*, Indo Am. J. P. Sci, 2019; 06[06].

INTRODUCTION:

Overweight is a body mass index between 25.0 to 29.9 kg/m². Obesity is a body mass index of 30 kg/m² or higher. Obesity and obesity are risk factors for hypertension, dyslipidemia, and diabetes mellitus. The Framingham Study demonstrated that obesity was about twice as prevalent in obese men and in obese women as in men and in women with a normal Metropolitan relative weight. The Framingham Study also demonstrated that both men and women had an increase in blood pressure with increased overweight [1].

Ghrelin is also called orexigenic and it is a peptide hormone released from the P/D1 cells in fundus in upper part of stomach and in the pancreas. Ghrelin secreting cells are also called epsilon cells. It is released when stomach is empty and its release is inhibited when stomach is stretched [2]. It's a potent appetite stimulant. Ghrelin effects on GIT and its motility, bone formation, cardiovascular cells and insulin as well. Previous studies show that its levels are low in obesity and also in hypertension; however ghrelin has important vascular and metabolic effects [3]. It increases the gastric secretion and gut motility as well. Ghrelinergic cells are located in stomach, jejunum, lungs; islets of Langerhans, adrenal cortex, placenta, and kidney and according to recent studies in brain as well. Ghrelin-O-acyl transferase (GOAT) is an enzyme which modifies the 3serine by n-octanoic acid to increase ghrelin activity and this enzyme. It was discovered by Yang, (2008), and is present in GIT and testis. Its optimum temp is 37-50 °C and pH between 7-8. Growth hormone, the receptors for Ghrelin are called growth hormone secretagogue receptor [4]. Its mRNA is present in arcuate (ARC), ventromedial nuclei (VMN) of hypothalamus and in hippocampus. It is a heterotrimeric G protein-coupled receptor (GPCR) containing 366 amino acids with the typical seven transmembrane domains.

Ghrelin receptor (GHSR1) is involved in biological effect of ghrelin including growth hormone release, increase in hunger lipid and glucose metabolism, increased regulation of motility and secretion of GIT, and protection of nervous and cardiovascular cells. It also plays a role in cell signaling mechanism [5].

Obesity related hypertension is a very common problem in our population. Ghrelin has enhanced the perception of feeding regulation, dietetic hemostasis and metabolic process. There are evidences that in future ghrelin and obestatin will most likely generate new pharmacological advancement to establish and treat different diseases including those correlates to the obesity and metabolism [6].

OBJECTIVES OF THE STUDY:

The main objective of the study is to analyze the role of Ghrelin among young hypertensive and obese patients.

METHODOLOGY OF THE STUDY:

This cross sectional study was conducted in Islamic International Medical College Rawalpindi (RIU) during August 2018 to March 2019. The data was collected from 100 patients. A fasting venous blood sample with a total volume of 4 ml will be collected from each study participant. One ml of this will be used in for routine testing FBS and 1 ml for fasting lipid profile. The remaining 2ml of blood sample will be collected in potassium/ethylene diamine tetracetic acid coated tubes containing 500 KIU aprotinin for the measurement of plasma levels of total ghrelin. Sample will be centrifuged at 2000g for 10 min. Plasma will be kept at -40 C until analyzed. Ghrelin levels will be determined using ELISA kit. Sensitivity of assay would be 8pg/ml for ghrelin.

STATISTICAL ANALYSIS:

Statistical analysis will be done on SPSS 20 software. Mean \pm SD will be given for quantitative variables. Comparisons between the groups will be done using t test. Level of significance will be taken as $p \leq 0.05$.

RESULTS:

The data was collected from 100 patients, 50 were obese and 50 were normotensive patients. Minimum age was age was 10 years and maximum age was 25 years with mean age 39.35 ± 10.086 years. Mean age of hypertensive obese was 43.42 ± 10.466 years and mean age of normotensive was 35.28 ± 7.876 years.

Table 01: Analysis of mean fasting ghrelin levels between hypertensive and normotensive obese

Group	n	Mean	Std. Deviation	P Value
Hypertensive obese	57	0.572	0.514	0.013
Normotensive obese	57	0.387	0.202	

Mean ghrelin levels in hypertensive obese was 0.572 ± 0.514 and mean ghrelin levels in normotensive obese was 0.387 ± 0.202 . Statistically significant difference of mean fasting ghrelin levels between hypertensive obese and normotensive obese was noted with p value 0.013.

Table 02: Comparison of mean fasting ghrelin levels for age group 10-25 years between hypertensive and normotensive obese

Group	n	Mean	Std. Deviation	P Value
Hypertensive obese	36	0.676	0.610	0.001
Normotensive obese	53	0.386	0.205	

DISCUSSION:

Obesity is known to be strongly associated with hypertension and other arteriosclerotic disease, but the pathogenic mechanisms linking hypertension and obesity have not been fully determined. The possible roles of obestatin and ghrelin in obesity and metabolic syndrome have been studied. Changes in the concentrations of these hormones, and in the ghrelin/obestatin ratio, may be risk factors for obesity and hypertension [7].

Ghrelin is a peptide hormone secreted primarily from the stomach and duodenum; it is a stimulant of appetite and increases adiposity in rodents. However, many studies have shown that obesity is associated with a decrease in circulating ghrelin. Ghrelin has also been reported to have potent anti-inflammatory actions, including inhibition of pro inflammatory cytokine production and mononuclear cell binding in vascular endothelial cells [8]. Ghrelin may therefore have a protective effect on endothelial function and has been shown to lower blood pressure levels. Low plasma ghrelin has been reported to be associated with insulin resistance, hypertension and type 2 diabetes [9].

Obestatin is a 23-amino acid amidated peptide encoded by the ghrelin gene that is also released from the stomach. It has been shown to interact with the orphan receptor G-protein-coupled receptor 39, and to oppose the stimulatory effect of ghrelin on food intake and gastrointestinal function. Studies in humans have shown that blood obestatin levels are significantly lower in obese subjects and correlate negatively with body mass index, insulin, glucose and the homeostasis model assessment of insulin resistance (HOMA-IR) [10], indicating an important role for obestatin in body weight regulation. In addition, obestatin has been shown to be positively correlated with ghrelin. This suggests that levels of both obestatin and ghrelin may be altered in obesity and insulin resistance [11].

CONCLUSION:

It is concluded that Ghrelin was positively associated with hypertension in obese patients and this association was inversely influenced by the increase of BMI.

REFERENCES:

1. Oner-Iyidoğan, Y., Koçak, H., Gürdöl, F., et al. 2007. Circulating ghrelin levels in obese women: a possible association with hypertension. *Scandinavian Journal of Clinical Laboratory Investigation*, 67: 568–576.
2. Rhéaume, C., Leblanc, M-È. and Poirier, P. 2011. Adiposity assessment: explaining the association between obesity, hypertension and stroke. *Expert Review Cardiovascular Therapy*, 9: 1557–1564
3. Sato, T., Nakamura, Y., Shiimura, Y., et al. 2011. Structure, regulation and function of ghrelin. *Journal of biochemistry*, 151 (2):119-128.
4. Carlson, S.H., and Wyss, J.M. 2011. Mechanisms underlying hypertension and obesity: a melanocortin linkage in the brain. *Hypertension*. 57: 375–376.
5. Guan, X-M., Yu, H., Palyha, O.C., Sirinathsinhji, D.J., Smith, R.G., Van der Ploeg, L.H., and Howard, A.D. 1997. Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissue. *Molecular Brain Research*. 48: 23 - 29.
6. Hall, J.E., Da, Silva, A.A., Do Carmo, J.M., et al. 2010. Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. *Journal of Biological Chemistry*, 285: 17271–17277.
7. Li, Z.F., Guo, F.L., et al. 2010. Circulating ghrelin and ghrelin to obestatin ratio are low in patient with untreated mild to moderate hypertension, 165: 206-209

8. Nakazato, M., Murakami, N., Date, Y., Kojima, M., Matsuo, H., Kangawa, K., and Matsukura, S. 2001. A role for ghrelin in the central regulation of feeding. *Nature*, 409: 194–198.
9. Wang, W.M., Li, S.M., et al. 2014. Ghrelin and obestatin levels in hypertensive obese patients. *Journal of International Medical Research*, 42 (6):1202-1208
10. Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H. and Kangawa, K. 1999. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. *Nature*, 402: 656–660.